Sammanfattning av aktiekursernas upp- och nedgångar samt förändringar för Bayer
Historiska aktiekurser
Aktuell aktiekurs	€38.51
52 veckors högsta	€49.78
52 veckors lägsta	€24.08
Beta	0.84
1 månads förändring	-4.30%
3 månaders förändring	-11.84%
1 års förändring	57.34%
3 års förändring	-29.21%
5 års förändring	-26.28%
Förändring sedan börsintroduktionen	182.76%

Senaste nyheter och uppdateringar

Uppdatering av berättelse • May 22

BAYN: Easing Litigation Risks Will Support Re Rating And Future Upside Potential

Analysts have maintained the fair value estimate for Bayer at €60.00 and raised price targets in recent research, citing a series of upgrades, slightly higher assumptions for revenue growth and profit margins, as well as a modestly lower future P/E multiple following a broad reassessment of sector risks and company-specific legal developments. Analyst Commentary Recent research points to a clear shift toward more constructive views on Bayer, with several bullish analysts updating ratings and valuation frameworks in response to company specific developments and sector wide reassessments.

Recent updates

Uppdatering av berättelse • May 22

BAYN: Easing Litigation Risks Will Support Re Rating And Future Upside Potential

Uppdatering av berättelse • May 05

BAYN: Future Litigation And Settlement Uncertainty Will Constrain Share Upside Potential

Analysts have nudged the fair value estimate for Bayer higher to about €31.26 from €30.41, citing a series of recent upgrades and higher price targets that reflect updated assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent Street research on Bayer has been mixed, with several firms updating ratings and price targets over the past few months.

Uppdatering av berättelse • Apr 21

BAYN: Future Litigation Settlement Payouts Will Pressure Upside Potential

Analysts have lifted the Bayer fair value estimate from €23.00 to about €30.41, citing a series of recent price target increases and upgrades that reflect updated assumptions for revenue growth, profit margins, and P/E expectations. Analyst Commentary Recent research on Bayer shows a split in sentiment, with some firms becoming more constructive while others highlight ongoing risks to the investment case.

Uppdatering av berättelse • Apr 06

BAYN: Roundup Settlement Progress Will Reduce Litigation Overhang And Support Future Upside

Analysts maintain a fair value estimate for Bayer at €60.00. Recent adjustments to revenue growth, margin, and P/E assumptions come alongside mixed research actions, including several upgrades that point to potential resolution of litigation overhangs and margin upside, offset by at least one downgrade with a lower price target.

Uppdatering av berättelse • Mar 23

BAYN: Roundup Settlement Advances Will Support Future Upside In Core Earnings

Analysts have modestly adjusted Bayer's price targets to a range of €50 to €55, reflecting mixed views that balance recent upgrades tied to share price weakness, litigation progress and margin potential with at least one more cautious stance. Analyst Commentary Recent research points to a cluster of more optimistic views on Bayer, with several bullish analysts raising ratings or price targets as they reassess litigation risk, product potential and profitability in key segments.

Uppdatering av berättelse • Mar 09

BAYN: Roundup Settlement Progress Will Support Future Upside In Core Earnings

Analysts have revised their view on Bayer with a reduced implied P/E and updated margin expectations, while recent Street research shows a split between a Sell call at €42 and an Overweight stance at €45 that hinges on litigation resolution and potential upside in pharmaceuticals and Crop Science. Analyst Commentary Recent research on Bayer highlights a clear divide between cautious and optimistic views, with valuation closely linked to how investors think litigation, pharmaceutical assets and Crop Science margins will play out.

Uppdatering av berättelse • Feb 23

BAYN: Roundup Settlement Progress Will Unlock Future Equity Upside

The analyst fair value estimate for Bayer has been adjusted to €60 from €55. This reflects updated assumptions on revenue growth and future P/E, alongside mixed Street views, including a downgrade citing valuation risks and an upgrade pointing to potential progress on litigation and margins.

Uppdatering av berättelse • Feb 09

BAYN: Litigation Overhang Resolution Will Unlock Future Equity Upside

Analysts have nudged their Bayer price targets higher, with recent moves such as Barclays shifting to an Overweight rating with a €45 target and Berenberg raising its target to €30.40. They cite potential resolution of litigation issues, along with possible upside in Kerendia and Crop Science margins, as key supports for their updated views.

Analysartikel • Jan 27

The Market Lifts Bayer Aktiengesellschaft (ETR:BAYN) Shares 29% But It Can Do More

Despite an already strong run, Bayer Aktiengesellschaft ( ETR:BAYN ) shares have been powering on, with a gain of 29...

Uppdatering av berättelse • Jan 25

BAYN: Litigation Resolution And Crop Science Margins Will Unlock Future Upside

Analysts have raised their fair value estimate for Bayer from €47.98 to €55.00, citing the potential resolution of litigation issues, improved expectations for Kerendia, and margin opportunities in the Crop Science business as key supports for the higher target. Analyst Commentary Recent Street research points to a more constructive tone around Bayer, with several bullish analysts adjusting their views in ways that support the higher fair value estimate.

Uppdatering av berättelse • Jan 09

BAYN: Litigation Overhang Will Drive Future Rerating Risk For Shares

Narrative Update Analysts have nudged their fair value estimate for Bayer from €33.42 to €34.97, citing updated assumptions for modestly higher revenue growth, slightly stronger profit margins, a higher future P/E, and growing confidence that litigation issues, Kerendia expectations, and Crop Science margins could be better than previously modeled. Analyst Commentary Recent Street research on Bayer has focused on how quickly the litigation overhang could be addressed, the role of Kerendia in the pharma portfolio, and the strength of margins in Crop Science.

Uppdatering av berättelse • Dec 26

BAYN Will Rely On Pipeline And Cost Cuts To Unlock Upside Potential

Analysts have raised their price target on Bayer to approximately EUR 48 from around EUR 37. They cite expectations for slightly faster revenue growth, improved profit margins, a modestly lower discount rate and a higher future earnings multiple that together support a higher fair value.

Uppdatering av berättelse • Dec 11

BAYN: Future Litigation Outcomes And Potential Ag Spin-Out Will Shape Shares

Analysts have nudged their Bayer price target higher to about EUR 30 from the mid‑20s, citing slightly faster expected revenue growth, modestly stronger profit margins, and a richer future P/E multiple. Together, these factors lift estimated fair value to roughly EUR 33 per share.

Analysartikel • Dec 03

Further Upside For Bayer Aktiengesellschaft (ETR:BAYN) Shares Could Introduce Price Risks After 27% Bounce

Bayer Aktiengesellschaft ( ETR:BAYN ) shareholders have had their patience rewarded with a 27% share price jump in the...

Uppdatering av berättelse • Nov 27

BAYN: Future Litigation Decisions And Agriculture Spin-Out Will Guide Shares

Bayer's analyst price target increased from EUR 28.71 to EUR 29.57, as analysts cite improved forecasts for revenue growth and a recent uptick in target valuations across the sector. Analyst Commentary Bullish Takeaways Bullish analysts have raised Bayer's price targets in response to improved revenue forecasts.

Analysartikel • Nov 14

Bayer Aktiengesellschaft (ETR:BAYN) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

It's been a pretty great week for Bayer Aktiengesellschaft ( ETR:BAYN ) shareholders, with its shares surging 13% to...

Uppdatering av berättelse • Nov 13

BAYN: Future Legal Outcomes And Sector Dynamics Will Determine Momentum

Analysts have raised Bayer's price target slightly from $28.53 to $28.71, reflecting steady profit margin improvements and updated industry positioning. This adjustment comes particularly in light of ongoing strategic shifts among major agribusiness peers.

Analysartikel • Jul 13

Is Bayer (ETR:BAYN) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Ny berättelse • Nov 24

Innovative Launches And Decisive Moves Set Stage For Remarkable Growth In Pharmaceuticals And Consumer Health

Pharmaceutical and agriculture innovations are key strategies for growth, offsetting generic competition and boosting future revenues.

Aktieägarnas avkastning

	BAYN	DE Pharmaceuticals	DE Marknad
7D	2.1%	6.1%	3.2%
1Y	57.3%	27.3%	2.5%

Avkastning vs industri: BAYN översteg German Pharmaceuticals branschen som gav 27.3 % under det senaste året.

Avkastning vs Marknaden: BAYN översteg German marknaden som gav 2.5 % under det senaste året.

Prisvolatilitet

Is BAYN's price volatile compared to industry and market?
BAYN volatility
BAYN Average Weekly Movement	4.8%
Pharmaceuticals Industry Average Movement	6.3%
Market Average Movement	6.1%
10% most volatile stocks in DE Market	13.6%
10% least volatile stocks in DE Market	2.7%

Stabil aktiekurs: BAYN har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för German.

Volatilitet över tid: BAYN s veckovolatilitet ( 5% ) har varit stabil under det senaste året.

Om företaget

Grundad	Anställda	VD OCH KONCERNCHEF	Webbplats
1863	87,757	Bill Anderson	www.bayer.com

Bayer Aktiengesellschaft är ett världsomspännande life science-företag. Företaget är verksamt inom segmenten Pharmaceuticals, Consumer Health och Crop Science. Segmentet Pharmaceuticals tillhandahåller receptbelagda produkter främst inom kardiologi och kvinnohälsovård, specialiserade läkemedel inom områdena onkologi, hematologi och oftalmologi, utrustning för bilddiagnostik och kontrastmedel samt cell- och genterapi.

Bayer Aktiengesellschaft Sammanfattning av grunderna

Hur förhåller sig Bayer:s resultat och omsättning till dess börsvärde?
BAYN grundläggande statistik
Börsvärde	€37.88b
Vinst(TTM)	-€2.16b
Intäkter(TTM)	€45.24b

0.8x

P/S-förhållande

-17.5x

P/E-förhållande

Är BAYN övervärderat?

Se Verkligt värde och värderingsanalys

Resultat & intäkter

Viktig lönsamhetsstatistik från den senaste resultatrapporten (TTM)
BAYN resultaträkning (TTM)
Intäkter	€45.24b
Kostnad för intäkter	€18.13b
Bruttovinst	€27.11b
Övriga kostnader	€29.26b
Intäkter	-€2.16b

Senast redovisade vinst

Mar 31, 2026

Nästa vinstdatum

Aug 04, 2026

Vinst per aktie (EPS)	-2.19
Bruttomarginal	59.92%
Nettovinstmarginal	-4.77%
Skuld/egenkapitalförhållande	134.3%

Hur har BAYN utvecklats på lång sikt?

Se historisk utveckling och jämförelse

Utdelningar

0.3%

Aktuell utdelningsavkastning

-5%

Utbetalningskvot

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/05/22 23:00
Aktiekurs vid dagens slut	2026/05/22 00:00
Intäkter	2026/03/31
Årlig intjäning	2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Bayer Aktiengesellschaft bevakas av 42 analytiker. 18 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Rafael Bonardell Trianes	Banco de Sabadell. S.A.
Emily Field	Barclays
Charles Pitman	Barclays

Bayer (BAYN) Aktievy

Belöningar

Riskanalys

Analyst Price Targets

Sustainable Farming And Rising Healthcare Will Fuel Expansion

Crop Science And Pharmaceuticals Will Suffer Under Mounting Liabilities

Crop Science And Pharmaceuticals Will Thrive On Favorable Trends

Top Community Narratives

Bayer to Achieve Fair Value of €40 Boosting Growth and Investor Confidence

Top Community Narratives

Bayer to Achieve Fair Value of €40 Boosting Growth and Investor Confidence

Top Analyst Narratives

Sustainable Farming And Rising Healthcare Will Fuel Expansion

Crop Science And Pharmaceuticals Will Suffer Under Mounting Liabilities

Crop Science And Pharmaceuticals Will Thrive On Favorable Trends

Bayer Aktiengesellschaft Konkurrenter

Merck KGaA

Dermapharm Holding

PEPTONIC medical

Sartorius

Prishistorik och prestanda

Senaste nyheter och uppdateringar

Bayer Presents New Data Across Oncology Portfolio

Bayer Announces Priority Review Of Supplemental New Drug Application For Kerendia For Treatment Of Adults With Type 1 Diabetes And Chronic Kidney Disease

BAYN: Easing Litigation Risks Will Support Re Rating And Future Upside Potential

Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After A Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack

Bayer Receives U.S. FDA Priority Review For Hyrnuo As First-Line Treatment Of Her2-Mutated Non-Small Cell Lung Cancer

Bayer Receives FDA Priority Review for HYRNUO in HER2-Mutated Lung Cancer

Recent updates

Bayer Presents New Data Across Oncology Portfolio

Bayer Announces Priority Review Of Supplemental New Drug Application For Kerendia For Treatment Of Adults With Type 1 Diabetes And Chronic Kidney Disease

BAYN: Easing Litigation Risks Will Support Re Rating And Future Upside Potential

Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After A Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack

Bayer Receives U.S. FDA Priority Review For Hyrnuo As First-Line Treatment Of Her2-Mutated Non-Small Cell Lung Cancer

Bayer Receives FDA Priority Review for HYRNUO in HER2-Mutated Lung Cancer

First quarter 2026 earnings released: EPS: €2.81 (vs €1.32 in 1Q 2025)

Bayer Announces Positive Topline Results from the Phase III REVEAL Study

Bayer Aktiengesellschaft (XTRA:BAYN) entered into an agreement to acquire Perfuse Therapeutics, Inc. for $2.5 billion.

BAYN: Future Litigation And Settlement Uncertainty Will Constrain Share Upside Potential

BAYN: Future Litigation Settlement Payouts Will Pressure Upside Potential

Upcoming dividend of €0.11 per share

BAYN: Roundup Settlement Progress Will Reduce Litigation Overhang And Support Future Upside

Bayer AG Announces Appointment of Nelson Ambrogio as President of U.S. Pharmaceuticals, Effective May 1, 2026

BAYN: Roundup Settlement Advances Will Support Future Upside In Core Earnings

Bayer Announces Kerendia Meets Primary Endpoint In Investigational Phase III Find-Ckd Study In Patients With Non-Diabetic Chronic Kidney Disease

Bayer Aktiengesellschaft to Report Q4, 2026 Results on Feb 24, 2027

BAYN: Roundup Settlement Progress Will Support Future Upside In Core Earnings

Bayer Aktiengesellschaft to Report Q3, 2026 Results on Nov 03, 2026

Dividend of €0.11 announced

Missouri Court Grants Preliminary Approval of Roundup Class Settlement to Resolve Current and Future Claims

Full year 2025 earnings: EPS misses analyst expectations

Bayer Aktiengesellschaft, Annual General Meeting, Apr 24, 2026

Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer

Bayer Announces XOFIGO (Radium-223 Dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit In PEACE-3 Trial In Patients With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases

BAYN: Roundup Settlement Progress Will Unlock Future Equity Upside

Monsanto Announces Roundup™ Class Settlement Agreement to Resolve Current and Future Claims

BAYN: Litigation Overhang Resolution Will Unlock Future Equity Upside

Bayer's Asundexian Demonstrated A Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo

Bayer to Present Results from Phase III Oceanic-Stroke Study of Asundexian in Secondary Stroke Prevention

The Market Lifts Bayer Aktiengesellschaft (ETR:BAYN) Shares 29% But It Can Do More

BAYN: Litigation Resolution And Crop Science Margins Will Unlock Future Upside

Price target increased by 14% to €39.87

BAYN: Litigation Overhang Will Drive Future Rerating Risk For Shares

Askbio Inc. Announces Fda Acceptance of Investigational New Drug (Ind) Application for Ab-1009 Gene Therapy for Treatment of Late-Onset Pompe Disease

BAYN Will Rely On Pipeline And Cost Cuts To Unlock Upside Potential

Price target increased by 7.6% to €34.18

BAYN: Future Litigation Outcomes And Potential Ag Spin-Out Will Shape Shares

Bayer Starts Phase IIa Study for Treatment of Patients with Alport Syndrome

Further Upside For Bayer Aktiengesellschaft (ETR:BAYN) Shares Could Introduce Price Risks After 27% Bounce

Price target increased by 7.4% to €31.21

Bayer Starts New Phase III Study with Mirena®? for the Treatment of Nonatypical Endometrial Hyperplasia

BAYN: Future Litigation Decisions And Agriculture Spin-Out Will Guide Shares

Bayer Announces Positive Topline Results from the Global Phase III Study Oceanic-Stroke, with Its Investigational, Once Daily, Oral FXIa Inhibitor asundexian

U.S. FDA Approves HYRNUO®? (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Bayer Aktiengesellschaft to Report Q2, 2026 Results on Aug 04, 2026

Bayer Aktiengesellschaft (ETR:BAYN) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Third quarter 2025 earnings: EPS misses analyst expectations

BAYN: Future Legal Outcomes And Sector Dynamics Will Determine Momentum

Bayer AG Announces Chief Financial Officer Changes

Bayer Announces New Phase III Investigational Data from the Pivotal Fine-One Trial